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Phthalates are industrial chemical additives
used primarily to soften and confer ﬂexibility
to plastics. In their pure form, phthalates are
clear, oily liquids that are highly lipophilic and
poorly soluble in water. They are a key compo-
nent in a wide range of products, including
but not limited to ﬂexible polyvinyl chloride
(PVC) plastics, vinyl tile, food packaging,
insecticides, pharmaceuticals, and personal care
products [Agency for Toxic Substances and
Disease Registry (ATSDR) 2001, 2002;
National Toxicology Program Center for the
Evaluation of Risks to Human Reproduction
(NTP-CERHR) 2003; Schettler 2006].
Because they are not chemically bound to the
plastics, phthalates can be released as the prod-
ucts are used and discarded. The Centers for
Disease Control and Prevention (CDC) meas-
ured urinary concentrations of phthalate
metabolites in representative samples of the
noninstitutionalized U.S. population, and for
several phthalates, detectable levels of their
metabolites were present in more than three-
quarters of the participants (CDC 2005).
These data conﬁrm that the general population
in the United States is exposed to phthalates.
Some animal studies suggest that at least
some phthalates are developmental and repro-
ductive toxicants (ATSDR 2001, 2002; NTP-
CERHR 2000a, 2000b, 2003, 2005), although
the effects on human health have not been
extensively described, and the effective toxic
doses of phthalates in these animal studies are
many times higher than typical human expo-
sures. Unusually high levels of exposure may
occur, however, among infants admitted to
neonatal intensive care units (NICUs), because
of their small body mass and the use of phtha-
late-containing medical devices in their care
(Calafat et al. 2004; Green et al. 2005). Of par-
ticular relevance is di(2-ethylhexyl) phthalate
(DEHP), which is used as a plasticizer in a vari-
ety of medical products (U.S. Food and Drug
Administration 2002), including those found
in the NICU, such as bags containing blood,
plasma, intravenous ﬂuids, and total parenteral
nutrition; tubing associated with their adminis-
tration; nasogastric tubes; enteral feeding
tubes; umbilical catheters; extracorporeal
membrane oxygenation (ECMO) circuit tub-
ing; hemodialysis tubing; respiratory masks
and endotracheal tubes; and examination
gloves. DEHP migrates out of the plastic into
blood or other lipid-containing solutions in
contact with the plastic, a phenomenon
observed with blood stored in PVC bags (Peck
and Albro 1982; Rock et al. 1984) and endo-
tracheal tubes (Latini and Avery 1999). The
rate of DEHP leaching depends on the type of
solution in contact with the plastic material
and on temperatures at the time of use, stor-
age time, and percent DEHP in the plastic
product (Marcel 1973). Overall, however,
estimates of infants’ exposure to DEHP from
common NICU devices exceed typical daily
adult exposure [3–30 µg/kg body weight
(bw)/day] (NTP-CERHR 2005) by one to
two orders of magnitude, approaching the
lowest observed adverse effect level (LOAEL)
in animal studies (14–23 mg/kg bw/day)
(NTP-CERHR 2005). The susceptibility of
neonates in the NICU to high DEHP expo-
sures may be compounded by their impaired
ability to clear phthalates from their bodies.
Until an age of 3 months, infants have imma-
ture glucuronidation pathways (Leeder and
Kearns 1997). Because glucuronidation, via
enzymes such as uridine diphosphate-glu-
curonosyltransferase, facilitates urinary excre-
tion of phthalates and other xenobiotics, a
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OBJECTIVE: We previously demonstrated that among 54 infants in neonatal intensive care units,
exposure to polyvinyl chloride plastic medical devices containing the plasticizer di(2-ethylhexyl)
phthalate (DEHP) is associated with urinary concentrations of mono(2-ethylhexyl) phthalate
(MEHP), a DEHP metabolite. In this follow-up report, we studied the neonates’ exposure to
DEHP-containing devices in relation to urinary concentrations of two other DEHP metabolites,
and to urinary concentrations of metabolites of dibutyl phthalate (DBP) and benzylbutyl phthalate
(BzBP), phthalates found in construction materials and personal care products. 
MEASUREMENTS: A priori, we classiﬁed the intensiveness of these 54 infants’ exposure to DEHP-
containing medical products. We measured three metabolites of DEHP in infants’ urine: MEHP
and two of its oxidative metabolites, mono(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP) and
mono(2-ethyl-5-oxohexyl) phthalate (MEOHP). We also measured monobutyl phthalate (MBP), a
metabolite of DBP, and monobenzyl phthalate (MBzP), a metabolite of BzBP. 
RESULTS: Intensiveness of DEHP-containing product use was monotonically associated with all
three DEHP metabolites. Urinary concentrations of MEHHP and MEOHP among infants in the
high-DEHP-intensiveness group were 13–14 times the concentrations among infants in the low-
intensiveness group (p ≤ 0.007). Concentrations of MBP were somewhat higher in the medium-
and high-DEHP-intensiveness group; MBzP did not vary by product use group. Incorporating all
phthalate data into a structural equation model confirmed the specific monotonic association
between intensiveness of product use and biologic measures of DEHP. 
CONCLUSION: Inclusion of the oxidative metabolites MEHHP and MEOHP strengthened the asso-
ciation between intensiveness of product use and biologic indices of DEHP exposure over that
observed with MEHP alone. 
KEY WORDS: di(2-ethylhexyl) phthalate (DEHP), infants, mono(2-ethylhexyl) phthalate (MEHP),
mono(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate
(MEOHP), monobenzyl phthalate (MBzP), monobutyl phthalate (MBP), neonatal intensive care
unit (NICU), phthalate, structural equation model. Environ Health Perspect 114:1424–1431
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to slower excretion and higher concentrations
of mono(2-ethylhexyl) phthalate (MEHP), a
metabolite of DEHP, in neonates than in older
children and adults. Neonates also have ele-
vated gastric lipase activity (Hamosh 1990),
which may enhance their ability to convert
DEHP to MEHP.
We recently demonstrated that the inten-
siveness of DEHP-containing product use in
NICU neonates is associated with higher expo-
sure to DEHP, as reﬂected in elevated urinary
concentrations of MEHP (Green et al. 2005).
Although the median urinary concentration of
MEHP among these neonates was ﬁve to seven
times the median concentrations observed in
the noninstitutionalized U.S. population
(CDC 2005), 20% of these neonates had
MEHP concentrations that were less than or
equal to the limit of detection (LOD), 0.87
ng/mL. The absence of detectable levels of
MEHP could have been caused by the relative
absence of exposure to DEHP among these
infants. However, MEHP is a minor urinary
metabolite of DEHP. Oxidative metabolites,
such as mono(2-ethyl-5-hydroxylhexyl) phtha-
late (MEHHP) and mono(2-ethyl-5-oxohexyl)
phthalate (MEOHP), are more abundant in
urine than is MEHP (Koch et al. 2004a,
2005). Specifically, MEHHP and MEOHP
appear in urine at levels at least ﬁve times as
great as does MEHP (Barr et al. 2003; Becker
et al. 2004; CDC 2005; Kato et al. 2004;
Koch et al. 2003b, 2004b; Silva et al. 2006)
and thus may be more sensitive than MEHP as
biomarkers of DEHP exposure.
In addition, as phthalate research has
expanded, investigations have adopted a panel
of several phthalate metabolites emanating
from a range of parent phthalates (e.g.,
Hoppin et al. 2004; Swan et al. 2005).
Although the metabolites can be analyzed sep-
arately, this approach does not acknowledge
their biologic relationships and independen-
cies. For example, exposure to DEHP results
in elevations in urinary concentrations of
MEHP, MEHHP, and MEOHP, but not
monobutyl phthalate (MBP), a metabolite of
dibutyl phthalate (DBP).
Therefore, in this follow-up report, we
studied the intensiveness of the same 54
neonates’ exposure to DEHP-containing med-
ical devices in relation to urinary concentra-
tions of two oxidative metabolites of DEHP.
We also evaluated urinary concentrations of
monobenzyl phthalate (MBzP), a metabolite
of benzylbutyl phthalate (BzBP), and MBP, a
metabolite of DBP and a minor metabolite of
BzBP (Anderson et al. 2001). Exposures to
DBP and BzBP have not been evaluated for
neonates in the NICU. Using a structural
equation model (SEM), we integrated infor-
mation from all five biomarkers to estimate
the relations among use of DEHP-containing
products, infants’ sex, and exposure to DEHP,
DBP, and BzBP.
Materials and Methods
Study population. We studied a convenience
sample of 54 infants enrolled from the level 3
NICUs at two major Boston, Massachusetts,
area hospitals, as previously described (Green
et al. 2005). Level 3 NICUs provide all new-
born care, including mechanical ventilation,
high-frequency ventilation, surgery, and cardiac
catheterization. We selected infants to reﬂect a
range of diagnoses (including congenital
anomalies and developmental and metabolic
abnormalities) and NICU care requirements
(including ventilation, enteral feedings, par-
enteral nutrition, and indwelling catheteriza-
tion). To be eligible for our study, infants must
have been in the NICU at least 3 consecutive
days before enrollment, have a corrected gesta-
tional age of ≤ 44 weeks, and have been born at
or transferred to either hospital between
1 March and 30 April 2003. Concerns regard-
ing the sensitivity of this research led to the
design and implementation of a data and sam-
ple collection protocol that was based on visual
inspection and did not include inspection of
the medical records. The study protocol and
methods were approved by the institutional
review boards of Harvard School of Public
Health, Brigham and Women’s Hospital, and
Massachusetts General Hospital.
Intensiveness of DEHP-containing product
use. As previously described (Green et al. 2005),
one of the study investigators took an inventory
of products in use for the care of each infant.
Before data collection, we deﬁned three levels of
intensiveness of DEHP-containing product use
(low, medium, and high) based on a review of
medical products typically used in both NICUs
and information provided by their manufactur-
ers with respect to DEHP content. Infants clas-
siﬁed as having low-intensiveness product use
were those receiving primarily bottle and/or
gavage feedings. The medium-intensiveness
group included infants receiving enteral feed-
ings by indwelling gavage tubes either continu-
ously or by bolus feedings; intravenous
hyperalimentation by indwelling percutaneous
intravenous central catheter (PICC) line,
broviac, or umbilical vessel catheter (UVC);
and/or nasal continuous positive airway pres-
sure by nasal prongs. The infants in the high-
intensiveness product use group included those
receiving continuous indwelling umbilical vein
catheterization, endotracheal intubation, intra-
venous hyperalimentation by the central venous
route (i.e., PICC line, broviac, UVC), and an
indwelling gavage tube (for gastric decompres-
sion). None of the infants changed product use
groups over the course of observation.
Assessment of phthalate metabolites in
urine. The observing investigator collected
spot urine samples at the end of each infant’s
observation period(s). A total of 82 urine
samples were collected from 54 infants. Two
or more replicate samples were available for 18
infants, and of these, replicate samples were
collected concurrently with the first samples
from four infants (i.e., the diaper yielded
enough urine for two vials), whereas 19 repli-
cate samples were collected 6–72 hr after the
first samples from 14 infants, the timing of
which was determined by the investigator’s
visiting schedule and the availability of urine
in an infant’s diaper. We used these replicate
samples to assess variability in urinary phtha-
late concentrations within individual infants.
Urine samples were collected by squeezing
the urine either from a cotton gauze placed in
the infant’s diaper at the beginning of the
observation period or from the cotton ﬁlling of
the diaper the infant wore during the period of
observation. The cotton gauze or the removed
cotton diaper ﬁlling was placed into a 3–5-cc
polypropylene syringe (Becton-Dickinson,
Franklin Lakes, NJ), the plunger was replaced,
and the urine was squeezed into a 2- or 4-cc
Nunc cryovial. Urine samples were frozen
within 4–6 hr at –35°C and shipped on dry ice
to the CDC for analysis.
Urine specimens were analyzed for 10
phthalate metabolites, including MEHP,
MEHHP, MEOHP, MBP, and MBzP at the
CDC (Atlanta, GA). Urinary concentrations
of the five other metabolites were generally
lower than the LOD for the amount of sample
used in the analytical measurements, so we do
not discuss these further. The analytical
method, described in detail by Silva et al.
(2004), involved the enzymatic deconjugation
of the phthalate metabolites from their glu-
curonidated form, followed by automated
solid-phase extraction. Reversed-phase high-
performance liquid chromatography was used
to separate the phthalate metabolites from
other components in the extracted urine. The
metabolites were quantified by isotope dilu-
tion–tandem mass spectrometry. Samples,
reagent blanks, and quality control (QC)
materials were processed identically. QC
materials were analyzed along with the study
samples to ensure the accuracy and reliability
of the data. QC materials of low concentra-
tion (QCL) and high concentration (QCH)
were prepared from a base urine pool, obtained
from multiple anonymous donors, dispensed
in 5-mL aliquots, and stored at –20°C. Each
QC material was characterized by repeated
measurements, spanned over several weeks,
to define the mean concentrations and the
95% and 99% control limits of each phtha-
late metabolite. Each analytical run included
QC materials, blanks, and unknown samples.
The concentrations of the replicate QCH
and QCL materials, averaged to obtain one
measurement of QCH and QCL for each
run, were evaluated using standard statistical
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phthalate concentrations below the LOD were
assigned a value of LOD divided by the square
root of 2.
Assessment of other variables. We collected
data, as available, on gestational age and
length of stay in the NICU. However, data on
these variables were incomplete for about half
of the infants because the sample collection
was anonymous and not based on review of
medical records. The interpretation of these
data is tenuous because of missing data, so we
do not present these results. The intensiveness
of DEHP-containing product use correlates
with the degree of support required and is in
this way a rough surrogate measure for illness
severity. Nonetheless, we were not able to dis-
tinguish levels of illness severity within group
of product use, again because of the study’s
anonymous design.
Statistical analysis. To evaluate the changes
in urinary phthalate concentrations in speci-
mens collected from the same infant, we com-
puted Spearman correlations between replicate
urine specimens. For unadjusted comparisons
of urinary phthalate concentrations by sex,
institution, and product use group, we used the
Kruskal-Wallis nonparametric test. In the ﬁrst
stage of analysis, we used multiple linear regres-
sion to compare urinary phthalate concentra-
tions across product use groups, adjusting for
institution and infants’ sex. To stabilize the
variances of the urinary phthalates, we used log-
transformed phthalate values as the dependent
variables in the regression models. Because log-
transformed values were used, the regression
parameters in the model are interpreted as a
proportion of urinary phthalate concentrations
in the reference group for a given independent
variable—for example, the urinary phthalate
concentration of the medium-product-use
group as a proportion of that in the low-
product-use group. We ﬁt one regression model
for each of the ﬁve metabolites.
Although conventional multiple regression
analyses produce informative results, several
shortcomings motivated us to seek alternative
methods. In particular, performing a separate
regression analysis for each metabolite increases
the probability of chance ﬁndings due to mul-
tiple testing, does not account for high correla-
tions between phthalate concentrations (e.g.,
MEHHP and MEOHP), and yields a rela-
tively large number of regression parameters to
be interpreted. Further, because the sample size
is small, it is of interest to use a statistical pro-
cedure that maximizes statistical power in test-
ing the association between independent
variables (product use, infants’ sex, and institu-
tion) and urinary phthalate metabolites. SEMs
with latent variables (Sánchez et al. 2005)
allow us to address these issues and, in addi-
tion, allow us to use replicate measurements of
a given metabolite.
We fit an SEM with latent variables
(Sánchez et al. 2005) as an alternative to the
conventional regression analyses. This model
assumes that there are two latent phthalate
exposures that are indirectly measured by the
five metabolites in the study, and that the
latent variables are affected by (i.e., regressed
on) the predictors of interest (product use,
infants’ sex, and institution). Additional para-
meters (i.e., factor loadings) are estimated in
order to translate between the outcomes’ scales.
For example, a concentration of 1 ng/mL of
MEHHP in a sample does not necessarily
imply that the concentration of MEHP will
also be 1 ng/mL.
Figure 1 illustrates the model fitted, and
the equations below specify the mathematical
representation. The latent variable labeled
“DEHP” can be said to represent the overall
DEHP dose absorbed by the infant, where the
underlying dose is measured indirectly by the
metabolites MEHP, MEOHP, and MEHHP.
Likewise, the latent variable labeled “DBP/
BzBP” represents the overall dose of DBP and
BzBP, which is measured indirectly by the
metabolites MBP and MBzP. (Modeling a
unique latent variable requires at least two
measurements of that variable, so to represent
DBP and BzBP as distinct entities in the SEM
would have required additional measures of
DBP and BzBP metabolites.) Formally, the
model is:
DEHP = β01 + β11EXPMED + β21EXPHI
+ β31HOSP + β41MALE + ξ1 [1]
DBP and BzBP = β02 + β12EXPMED
+ β22EXPHI + β32HOSP
+ β42MALE + ξ2 [2]
ln(MEHHP) = DEHP + ε11 [3]
ln(MEOHP) = ν21 + λ12DEHP + ε12 [4]
ln(MEHP) = ν31 + λ13DEHP + ε13 [5]
ln(MBP) = DBP + ε21 [6]
ln(MBzP) = ν22 + λ33DBP + ε22. [7]
The β-values are the parameters of interest as
they represent the effects of product use, sex,
and institution on the latent phthalate expo-
sures. Equations 3–7 imply that the metabo-
lites measure the underlying parent phthalate
exposures with error (ε values), and that the
relations between the parent phthalates and
metabolites can have different scales (λ values).
For purposes of interpretation, the model
assumes, in Equations 3 and 6, that DEHP is
measured in ln(MEHHP) units and that DBP
is measured in ln(MBP) units (e.g., Budtz-
Jørgensen et al. 2002; Sánchez et al. 2005).
Therefore, Equation 3 says that a one-unit
change in DEHP results in one-ln(MEHHP)-
unit change, whereas Equation 4 says one unit
change in DEHP results in a λ12-unit change
in ln(MEOHP). Maximum-likelihood estima-
tion for all model parameters was done in
Mplus (Muthén and Muthén 1999–2004).
Where available, we incorporated into our
SEM analyses up to two replicate measure-
ments per infant for a given metabolite.
Results
As reported previously (Green et al. 2005), the
54 infants in our study were roughly equally
distributed between the two institutions, and
34 (63%) were female. Thirteen (24%) infants
were exposed to DEHP-containing products at
Weuve et al.
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Figure 1. SEM describing associations we tested among external predictors and phthalate metabolites
using two latent variables. The latent variable DEHP represents exposure to DEHP, which is measured by
three urinary phthalate metabolites. The latent variable DBP/BzBP represents exposure to DBP and BzBP,






































associationlow intensiveness, 24 (44%) were exposed at
medium intensiveness, and 17 (32%) were
exposed at high intensiveness. Among the ﬁrst
set of urine samples collected from these
infants, only 9% had concentrations of
MEHHP and MEOHP less than the LOD,
compared with 20% who had concentrations of
MEHP less than the LOD. Nearly all infants
had detectable concentrations of MBzP.
Maximum concentrations of MEHHP,
MEOHP, MBP, and MBzP were 3,492, 3,376,
257, and 971 ng/mL, respectively. Overall, uri-
nary concentrations of the three DEHP
metabolites among the neonates in our study
tended to exceed concentrations among persons
≥ 6 years of age, examined as part of the
National Health and Nutrition Examination
Survey (NHANES) (CDC 2005). Several stud-
ies, including NHANES, have reported some-
what elevated urinary concentrations of these
metabolites among noninstitutionalized chil-
dren in comparison with typical adult concen-
trations (Becker et al. 2004; CDC 2005; Koch
et al. 2004b), but the median DEHP metabo-
lite concentrations among the neonates in our
study were even an order of magnitude higher
than median concentrations found among these
children (Table 1). The neonates’ urinary con-
centrations of MBP were slightly lower than
those observed in other children and adult pop-
ulations (Brock et al. 2002; CDC 2003), and
although their concentrations of MBzP tended
to exceed concentrations among the population
overall, these concentrations were closer to
those observed among other children (Brock
et al. 2002; CDC 2005; Koch et al. 2005).
Correlation between urinary phthalate
metabolite concentrations in replicate urine
samples. Among the infants with multiple
urine samples, urinary phthalate measurements
from the same infants were highly correlated.
Spearman correlations between phthalate lev-
els in the first and second specimens ranged
from 0.61 (MBP; p = 0.007; n = 18) to 0.89
(MEHP; p < 0.0001; n = 17). Likewise, corre-
lations between phthalate concentrations in
the second and third specimens and ﬁrst and
third specimens tended to be strong as well
(Table 2), although interpretation is limited by
the small sample size (n = 5). We observed
modest attenuation in the correlations between
phthalate concentrations in urine specimens
collected at different times compared with
phthalate concentrations in specimens col-
lected at the same time, although our data were
limited to make a formal comparison (n = 4;
data not shown).
Correlations between different urinary
phthalate metabolites. Urinary concentrations
of the DEHP metabolites MEHP, MEHHP,
and MEOHP were more highly correlated with
each other than with the two other phthalate
metabolites measured (Table 2). The correla-
tion was particularly striking between MEHHP
and MEOHP, two oxidation products of
MEHP [Spearman correlation (r) = 0.95, p <
0.0001]. The DEHP metabolites were weakly
correlated with MBP and MBzP, in contrast
with the stronger correlation between MBP and
MBzP (r = 0.80, p < 0.0001).
Bivariate (unadjusted) associations between
urinary phthalates and DEHP exposure group,
sex, and institution. With increasing intensive-
ness of DEHP product use, we observed pro-
gressively higher concentrations of both
MEHHP (p = 0.0002; Table 3) and MEOHP
(p = 0.0003) in infants’ urine. These associa-
tions are consistent with the previously
described findings for MEHP (p = 0.001).
Median urinary MEHHP concentrations (and
25th and 75th percentiles) among infants in the
low-, medium-, and high-intensiveness product
use groups were 27 (18, 60), 307 (34, 614),
and 555 (328, 844) ng/mL, respectively;
median urinary MEOHP concentrations
among infants in these groups were 29 (11, 42),
286 (25, 611), and 598 (318, 906) ng/mL,
respectively. In contrast, in these unadjusted
analyses, no consistent associations were present
between intensiveness of product use and
urinary concentrations of MBP and MBzP.
Similar to the pattern of associations
between intensiveness of product use and uri-
nary phthalates, urinary MEHHP and
MEOHP (and MEHP) concentrations were
signiﬁcantly higher among infants at institu-
tion B (p ≤ 0.007), but concentrations of MBP
and MBzP were similar across institutions.
Overall, urinary phthalate concentrations did
not vary substantially by infants’ sex.
Adjusted associations between urinary
phthalates and DEHP exposure group, sex,
and institution. After adjusting for infants’
sex and institution of hospitalization, the
association between intensiveness of DEHP-
containing product use and both MEHHP
and MEOHP persisted. Although the previ-
ously reported association between product
use group and MEHP concentrations was
strongly suggestive (p = 0.07), the associa-
tions between product use group and both
MEHHP and MEOHP concentrations were
highly significant (Table 4). Compared with
infants exposed to DEHP-containing products
Exposure to phthalates in NICU infants
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Table 1. Distribution of phthalate metabolites (in nanograms per milliliter unless otherwise speciﬁed).
Phthalate parent compound/metabolite
DEHP DBP BzBP
No. MEHP MEHHP MEOHP MBPa MBzP
Distribution of ﬁrst phthalate measurements (n = 54)
LODb 0.87 1.6 1.2 0.94 0.8
No. < LOD (%) 11 (20) 5 (9.3) 5 (9.3) 11 (20) 2 (3.7)
Geometric mean (SD) 15 (7.6) 133 (8.4) 120 (9.2) 14 (6.0) 43 (5.1)
25th percentile 3 32 28 7 14
Median 22 267 256 18 41
75th percentile 71 644 628 45 131
Median urinary phthalate concentrations from other studies
United States
Children, 6–11 years of agec 393 4.4 32.9 22.6 40.0 37.0
Infants, 12–18 months of age (Brock et al. 2002)d 19 —e NA NA 29.0 20.2
Germany
Children, 3–14 years of age (Becker et al. 2004) 254 7.2 52.1 39.9 NA NA
Children, 3–7 years of age (Koch et al. 2004b, 2005) 36 6.6 49.6 33.8 NA 22.1
For comparison, persons ≥ 6 years of agec 2,782 4.1 20.1 14.0 26.0 15.7
NA, not available.
aMBP is also a metabolite of BzBP, albeit to a far lesser degree than of DBP. bThe LODs are the same across ﬁrst, second,
and third measurements. cFrom NHANES, 2001–2002 (CDC 2005). Because this report provided separate estimates for
mono-n-butyl phthalate and monoisobutyl phthalate, rather than a combined MBP value, we drew MBP estimates from
the NHANES 1999–2000 report (n = 328 children and 2,541 total) (CDC 2003). dComputed from reported results for each
child. eWe did not compute a median for MEHP, because more than half of the children had levels < LOD, which was as
high as 12 ng/mL. 




MEHP MEHHP MEOHP MBPa MBzP
Spearman correlation between repeated measurements
1st vs. 2nd (n) 0.89 (17) 0.85 (18) 0.80 (18) 0.61 (18) 0.81 (18)
2nd vs. 3rd (n) 0.90 (5) 0.90 (5) 1.00 (5) 0.87 (5) 0.90 (5)
1st vs. 3rd (n) 0.70 (5) 0.30 (5) 0.80 (5) 0.15 (5) 0.90 (5)
Spearman correlations between phthalate metabolites, among ﬁrst measurements
MEHHP 0.61
MEOHP 0.56 0.95
MBP 0.19 0.45 0.41
MBzP 0.03 0.39 0.40 0.80
aMBP is also a metabolite of BzBP, albeit to a far lesser degree than of DBP.at low intensiveness, infants exposed at
medium intensiveness had urinary MEHHP
concentrations that were 4.5 times as high
[95% conﬁdence interval (CI) of the multipli-
cation factor, 1.2–16.5; p = 0.02], and infants
exposed at high intensiveness had concentra-
tions that were 14.1 times as high (95% CI of
the multiplication factor, 3.3–61.0; p =
0.007). The association between product use
group and urinary concentrations of MEOHP
was similar in pattern and magnitude. We
observed a suggestive pattern in the distribu-
tion of urinary MBP: Compared with infants
exposed at low intensiveness, concentrations
of MBP were nearly four times as high among
infants exposed at medium (p = 0.05) and
high intensiveness (p = 0.07). Concentrations
of MBzP did not vary signiﬁcantly by product
use group. We obtained nearly identical ﬁnd-
ings when we conducted separate analyses for
each institution.
The institutional pattern of DEHP
metabolite distribution remained on adjust-
ment as well. On average, urinary concentra-
tions of MEHHP and MEOHP (and MEHP)
among infants hospitalized at institution B
were three times as great as concentrations
among infants at institution A (p-value range,
0.03–0.06). Although male infants tended to
have higher urinary concentrations of MEHP,
this pattern was not apparent with respect to
the two other DEHP metabolites or with
respect to MBP and MBzP.
Model of phthalate exposure incorporating
all measured phthalate metabolites. The asso-
ciation between intensiveness of DEHP-con-
taining product use and the latent variable
representing DEHP exposure was monotonic
and strongly signiﬁcant (p = 0.001) (Figure 1,
Tables 5 and 6). In units of MEHHP, the rel-
ative level of exposure to DEHP among
infants in the medium-intensiveness product
use group was 4.7 times that among infants in
the low-intensiveness group (95% CI for mul-
tiplication factor, 1.5–15), and among infants
in the high-intensiveness group, exposure to
DEHP was 14 times as great (95% CI for
multiplication factor, 3.9–50; Figure 1). The
association between product use and
DBP/BzBP did not follow a consistent pattern
and was not signiﬁcant (p = 0.2).
Infants at institution B had nearly three
times the DEHP exposure (in units of urinary
MEHHP) of infants at institution A (95% CI
for multiplication factor, 1.1–7.3; p = 0.05).
There were no significant differences in
DEHP exposure by sex. The associations
between DBP/BzBP and hospital or sex were
not signiﬁcant.
Discussion
In our study of 54 infants receiving care in two
NICUs, we found strong monotonic associa-
tions between the use of DEHP-containing
medical devices and urinary concentrations of
three metabolites of DEHP. These results rein-
force and expand the association we reported
previously with respect to MEHP (Green et al.
2005). Speciﬁcally, after adjustment for infants’
sex and institution, urinary MEHHP and
MEOHP concentrations among infants who
were exposed to DEHP-containing products at
high intensiveness were > 13 times that of
those in the low-intensiveness group. By com-
parison, as reported previously, concentrations
of MEHP in the high-intensiveness group were
ﬁve times that of those in the low-intensiveness
group. Urinary MEHHP and MEOHP con-
centrations among infants who were exposed
to DEHP-containing products at medium
intensiveness were more than four times that
of those in the low-intensiveness group. We
established the specificity of the association
between intensiveness of DEHP-containing
product use and exposure to DEHP using an
SEM, where we accounted not only for
infants’ sex and institution, but also for uri-
nary concentrations of two phthalate metabo-
lites emanating from parent compounds other
than DEHP, as well as up to two repeated
measures of all of the urinary metabolites. The
resulting parameters of this model conﬁrmed
the graded association between intensiveness
of DEHP product use and direct evidence of
exposure to DEHP, provided by the three
DEHP metabolites. Comparably absent in
these results was a monotonic association
between DEHP product use and combined
exposure to DBP and BzBP.
Exposure to DEHP was also higher among
infants hospitalized at institution B than
among infants hospitalized at institution A,
independent from DEHP product use group.
We speculate that this finding reflects the
extensive use in particular of two DEHP-con-
taining items at institution B: PVC indwelling
endotracheal tubes, and a PVC indwelling
hemodynamic monitoring UVC used for,
among other things, parenteral nutrition.
These DEHP-containing medical devices were
sparingly used in institution A.
There has been interest in estimating the
daily intake of DEHP using urinary concen-
trations of its metabolites and urinary creati-
nine. All 17 infants in the high-intensiveness
product use group had urinary creatinine
measurements concurrent with their urinary
phthalate measurements. In turn, urinary crea-
tinine measurements were available for only
62% and 92% of infants in the low- and
medium-intensiveness product use group,
respectively. Therefore, we estimated the
DEHP dose for the infants in the high-inten-
siveness product use group. Using the formula
expressed by Koch et al. (2003a) based on the
method of David (2000), and assuming a uni-
form creatinine clearance rate of 9.8 mg/kg
bw/day (Tietz 1990) and molar conversion
factors (which relate urinary excretion of
metabolite to diester ingested) of 0.23
(MEHHP) and 0.15 (MEOHP) (Koch et al.
2005), we estimated a median daily intake of
DEHP among the infants in the high-inten-
siveness product use group ranging from 233
to 352 µg/kg bw/day based on MEHHP and
Weuve et al.
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Table 3. Median (and 25th and 75th percentile) concentrations of urinary phthalate metabolites (ng/mL), by intensiveness of DEHP-containing product use, institu-
tion, and sex.
Urinary MEHP Urinary MEHHP Urinary MEOHP Urinary MBP Urinary MBzP
25th Median 75th p-Valuea 25th Median 75th p-Valuea 25th Median 75th p-Valuea 25th Median 75th p-Valuea 25th Median 75th p-Valuea
Intensiveness of DEHP-containing product use (n)
Low (13) < LODb 41 8 1 82 76 0 1 12 94 2 <  L O D b 12 19 15 41 47
Medium (24) 3 28 61 34 307 614 25 286 611 7 22 70 21 70 256
High (17) 21 86 171 328 555 844 318 598 906 12 20 45 10 36 82
0.001 0.0002 0.0003 0.2 0.6
Institution (n)
A (28) < LODb 12 29 18 91 377 12 71 450 10 21 44 16 43 135
B (26) 18 58 92 231 381 844 187 472 738 < LODb 15 62 10 40 131
0.002 0.007 0.004 0.3 0.8
Sex (n)
Female (34) 3 20 64 32 267 644 36 286 598 10 18 35 28 50 131
Male (20) 19 39 75 26 277 671 19 315 674 7 20 45 10 25 98
0.15 0.9 0.9 0.8 0.2
Overall 3 22 71 32 267 644 28 256 628 7 18 45 14 41 131
25th and 75th are percentiles.
aFrom the Kruskal-Wallis nonparametric test for differences in phthalate distribution. bLOD: 0.87 ng/mL for MEHP and 0.94 ng/mL for MBP.MEOHP concentrations, respectively. This
level of intake is one to two orders of magni-
tude above typical adult exposures and higher
than the U.S. Environmental Protection
Agency’s (EPA) reference dose of 20 µg/kg
bw/day (U.S. EPA 2000), although still two
orders of magnitude below the LOAEL
observed in animal studies (14–23 mg/kg
bw/day; NTP-CERHR 2005). The DEHP
estimated dose for the infants in the medium-
and low-intensiveness product use groups
would be approximately 2- and 20-fold lower.
Nonetheless, because of the assumptions used
to compute ingested DEHP dose (e.g., uniform
vs. individual-speciﬁc creatinine clearance rate
and molar conversion factors calculated for one
adult male after oral ingestion of DEHP), these
estimates should be interpreted with caution.
In these first reported data on MBP and
MBzP among neonates, we present two inter-
esting ﬁndings. First, overall, although infants’
urinary concentrations of MBP were slightly
lower than those observed in a recent survey of
the U.S. population, their concentrations of
MBzP were somewhat higher. For example,
the median and 75th percentile concentrations
of urinary MBzP in our infants were 41 and
131 ng/mL, versus 15.7 and 38.0 ng/mL in the
U.S. population (CDC 2005). Moreover, the
infants’ median MBzP concentration was
nearly twice the median concentration observed
among 36 toddlers, 3–7 years of age, in
Germany (Koch et al. 2005). BzBP is com-
monly used in vinyl flooring, adhesives,
sealants, car-care products, and some personal
care products (NTP-CERHR 2003); and
although some of these products, particularly
vinyl ﬂooring, may be present in the NICU, we
did not specifically examine the sources and
routes of these neonates’ exposure to BzBP for
this study. Second, the modest association
between medium- and high-intensiveness prod-
uct use and urinary concentrations of MBP was
unexpected. It is unlikely that the products we
enumerated contained DBP; instead, the use of
these products may have coincided with other
exposures to DBP.
To date, few reports have described human
neonatal exposures to phthalates (Calafat et al.
2004; Green et al. 2005; Hillman et al. 1975),
and to our knowledge, no study has examined
whether such exposures are associated with
adverse health effects in these neonates. Limited
data describe the effects of neonatal exposures
to phthalates on health later in life. A study of
18 adolescents, 14–16 years of age, who had
undergone ECMO as neonates found no
apparent abnormalities in their growth and
pubertal maturity, and the levels of luteinizing
hormone, follicle-stimulating hormone, testos-
terone (in boys), and estradiol (in girls) were
within the normal reference ranges for stage of
pubertal development (Rais-Bahrami et al.
2004). It is difﬁcult to draw deﬁnitive conclu-
sions from this study, because it was very small,
and normal reference ranges for reproductive
hormones, physical growth, and sexual matura-
tion are quite wide. Furthermore, the postnatal
levels of DEHP or its metabolites at the time of
the ECMO treatment were not known. Several
recent epidemiologic studies suggest that phtha-
lates may be human reproductive and develop-
mental toxicants. In the only study, to our
knowledge, that has examined phthalate expo-
sure among infants (Main et al. 2006), 130
mothers in Denmark and Finland collected
aliquots of their breast milk from infant feed-
ings for several weeks starting 1 month after
their sons were born. Concentrations of phtha-
late monoesters in the mothers’ breast milk
were correlated with markers of Leydig cell
function measured in the sons when they were
3 months old: Higher phthalate concentrations
were correlated with higher sex-hormone bind-
ing globulin and ratio of luteinizing hormone
to testosterone, and with lower free testos-
terone. Breast milk phthalate concentrations
were not associated with cryptorchidism or
markers of Sertoli cell function in the sons
(Main et al. 2006). Other human reproductive
and developmental toxicity studies have
explored prenatal and adult exposures (Duty
et al. 2003; Swan et al. 2005) and not early
postnatal exposure.
Although data in humans are sparse as of
yet, the toxicity of DEHP to testicular develop-
ment and function has been well described in
male animals (NTP-CERHR 2000a, 2005),
and emerging data indicate that DEHP has
Exposure to phthalates in NICU infants
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Table 5. SEM-derived adjusted relative level of exposure to parent phthalates (95% CI), by intensiveness of
DEHP-containing product use, sex, and institution.
DEHP DBP and BzBP combined
Intensiveness of DEHP-containing product use
Low 1.0 (Referent)a 1.0 ( Referent)d
Medium 4.7 (1.5–15)a 2.5 (0.9–7.4)d
High 14 (3.9–50)a 1.8 (0.6–6.2)d
Infant's sex
Female 1.0 ( Referent)b 1.0 ( Referent)e
Male 0.8 (0.3–2.1)b 0.6 (0.3–1.4)e
Institution 
A 1.0 ( Referent)c 1.0 ( Referent)f
B 2.8 (1.1–7.3)c 0.8 (0.3–1.9)f
All comparisons were adjusted for the variables listed. The adjusted relative DEHP and DBP/BzBP exposures are
expressed in the scales of urinary MEHHP and MBP concentrations, respectively. For example, after adjusting for sex and
institution, exposure to DEHP among infants in the high product use group was about 14 times that among infants in the low
product use group, using MEHHP concentrations as the scale. These results may be expressed in units of the other com-
pounds by using the scales shown in Table 6; use of different scales does not alter the statistical signiﬁcance of the results. 
aResults correspond to arrow [a] in Figure 1. bResults correspond to arrow [b] in Figure 1. cResults correspond to arrow
[c] in Figure 1. dResults correspond to arrow [d] in Figure 1. eResults correspond to arrow [e] in Figure 1. fResults corre-
spond to arrow [f] in Figure 1. 
Table 6. Relative scale of phthalate metabolites










In Table 5, the relative exposures to the parent compounds,
DEHP and the combination of DBP and BzBP, are
expressed in units of MEHHP and MBP, respectively. To
express those results in the scale of a different metabolite,
use the following: exp[(relative scale) × ln(adjusted relative
parent compount exposure)], where relative scales are
shown above.
aResults corresond to arrow [1] in Figure 1. bResults cor-
resond to arrow [2] in Figure 1. cResults corresond to arrow
[3] in Figure 1. 
Table 4. Adjusted relative concentration of urinary phthalate metabolite (95% CI), by intensiveness of
DEHP-containing product use, sex, and institution. 
MEHP MEHHP MEOHP MBP MBzP
Intensiveness of DEHP-containing product use
Low 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 ( Referent)
Medium 2.0 (0.6–6.9) 4.5 (1.2–16.5) 4.4 (1.1–17.3) 3.6 (1.0–13.0) 2.1 (0.6–6.9)
High 5.0 (1.3–20.0) 14.1 (3.3–61.0) 13.1 (2.8–61.3) 3.8 (0.9–16.2) 1.5 (0.4–5.9)
Overall differences among
DEHP groups (p-value) 0.07 0.003 0.006 0.12 0.5
Infant’s sex
Female 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 ( Referent)
Male 2.5 (0.9–6.8) 0.8 (0.3–2.3) 0.9 (0.3–2.6) 0.9 (0.3–2.7) 0.6 (0.2–1.5)
Institution
A 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 ( Referent)
B 3.2 (1.1–9.0) 2.8 (1.0–8.5) 3.2 (1.0–10.0) 0.4 (0.1–1.1) 0.9 (0.3–2.5)
Estimates are multiplication factors derived from regression models of log-transformed urinary phthalates. They compare
urinary levels of a given phthalate in the medium and high DEHP exposure groups with levels in the low DEHP exposure
group, as well as comparing levels of a given phthalate by infants’ sex and institution. All comparisons are adjusted for the
variables listed. See “Materials and Methods” for details. Weuve et al.
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hypoestrogenic effects in female animals
(Lovekamp-Swan and Davis 2003); DEHP
may impair the function of other organs, as
well, including the kidney (ATSDR 2002).
Although MEHP partially mediates DEHP’s
reproductive toxicity (ATSDR 2002;
Lovekamp-Swan and Davis 2003), preliminary
evidence on the toxicity of MEHHP and
MEOHP is mixed (Gray and Gangolli 1986;
Stroheker et al. 2005). Appreciation of the
potential effects of MEHP, MEHHP, and
MEOHP is of particular relevance among
infants because of their elevated gastric lipase
activity (Hamosh 1990) (which promotes the
digestion of milk fats and, concomitantly, the
conversion of DEHP to MEHP) and impaired
capacity for glucuronidation (Leeder and
Kearns 1997) (which delays the excretion of
DEHP and its metabolites). Because very low-
birth-weight infants, resulting from preterm
deliveries, comprise a large proportion of the
NICU population, concern exists regarding
risks from high perinatal DEHP exposure.
Speciﬁcally, in the very preterm infant, DEHP
may adversely affect male reproductive tract
development, including testicular descent,
which occurs late in the third trimester (Hutson
et al. 1997).
Similar to DEHP and MEHP, DBP
appears to exert adverse reproductive effects in
male and female animals, mediated through its
metabolite MBP (NTP-CERHR 2000b).
Recent data suggest that neonatal exposure to
DBP impairs the development of sex organs
and alters the expression of steroid receptors in
male rats (Kim et al. 2004). At very high doses,
BzBP also is a reproductive toxin, particularly
in male animals (NTP-CERHR 2003). In a
study of 85 pregnant women (Swan et al.
2005), prenatal urinary concentrations of MBP
and, to a lesser extent, MBzP were associated
with signiﬁcantly shorter anogenital distance in
their infant sons. Inverse associations were also
present for urinary MEHP, MEHHP, and
MEOHP, but these were not statistically sig-
niﬁcant. This study examined prenatal expo-
sures to phthalates, and still, as with DEHP,
data on the health effects of human neonatal
exposure to DBP and BzBP are limited.
The present study’s small size, narrow range
of descriptive data on the infants, and lack of
environmental measures from the infants’
NICU environment limited our ability to con-
duct more detailed analyses. Nonetheless, our
study is the ﬁrst to demonstrate that increasing
intensiveness of DEHP-containing product use
is directly proportional to biologic exposure to
DEHP, reﬂected in stepwise elevations in uri-
nary concentrations of three DEHP metabolites
and in the absence of similar elevations in uri-
nary concentrations of two phthalate metabo-
lites from different parent compounds. It is also
the ﬁrst study to describe neonates’ exposure to
DBP and BzBP.
In our SEM, we were unable to distinguish
exposure to DBP from exposure to BzBP, lim-
iting our ability to examine further the sugges-
tive association observed in the conventional
regression results between the two highest
product use groups and urinary MBP. Such an
examination would have required additional
measures of DBP exposure, as was the case for
DEHP. Yet the application of SEMs to our
data revealed a potential drawback of using uri-
nary MEHP as the sole biomarker of DEHP
exposure. The measurement of urinary
MEHHP and MEOHP concentrations added
precision to estimated DEHP exposure, and
given that these metabolites were detectable in
more specimens, they may be more sensitive
measurements of DEHP, as noted by others
(Barr et al. 2003; Kato et al. 2004; Koch et al.
2003b, 2004a, 2004b, 2005; Silva et al. 2006).
Nonetheless, given MEHP’s known biologic
activity, it should continue to be measured in
future studies.
Conclusion
Measuring a panel of phthalate metabolites in
the urine of neonates in two NICUs, we con-
ﬁrmed and demonstrated the speciﬁcity of the
monotonic association between the intensive-
ness of DEHP-containing product use in their
care and exposure to DEHP. High DEHP
exposure levels in this sensitive population of
patients and concerns about DEHP toxicity
may justify routinely using available DEHP-
free products that do not otherwise compro-
mise the quality of care. We also reported a
modest elevation in urinary MBP among
infants receiving more intensive care. Future
work should establish the sources and ramiﬁ-
cations of these exposures, if any, on the devel-
opment of similar neonates.
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